SCHEMBL3582428

SCHEMBL3582428

Nc1cccc(Cc2ccc3c(c2)C(=CNc2cccc(O)c2)C(=O)N3)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
PDPK1 O15530 8/20 0.40
AKT2 P31751 3/20 0.40
TGM2 P21980 1/20 0.40
NTRK1 P04629 1/20 0.39
MAP3K7 O43318 1/20 0.39
TAB1 Q15750 1/20 0.39
PLK4 O00444 1/20 0.38
PLK1 P53350 1/20 0.38
ALK Q9UM73 2/20 0.37
RET P07949 1/20 0.37
FLT3 P36888 1/20 0.37
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
FLT1 P17948 1/20 0.37
KDR P35968 1/20 0.37
S1PR4 O95977 1/20 0.37
HSP90AA1 P07900 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4759187 0.93 ALDH1A1 (0.45) ALDH1A1CYP1A2CYP3A4PDPK1AKT2
SCHEMBL3582425 0.87 AKT2 (0.44) ALDH1A1CYP1A2CYP3A4PDPK1AKT2
SCHEMBL3579187 0.86 ALK (0.39) ALDH1A1PDPK1AKT2TGM2NTRK1
SCHEMBL4759184 0.86 AKT2 (0.43) ALDH1A1CYP1A2CYP3A4PDPK1AKT2
SCHEMBL4756702 0.85 GSK3B (0.50) ALDH1A1CYP1A2CYP3A4PDPK1AKT2
SCHEMBL4756700 0.85 GSK3B (0.50) ALDH1A1CYP1A2CYP3A4PDPK1AKT2
SCHEMBL3579647 0.84 NOX4 (0.41) PDPK1AKT2NTRK1RETMAPT
SCHEMBL4704718 0.83 GSK3B (0.50) ALDH1A1CYP1A2CYP3A4PDPK1AKT2
SCHEMBL5425612 0.83 GSK3B (0.50) ALDH1A1CYP1A2CYP3A4PDPK1AKT2
SCHEMBL3584603 0.82 MAP3K7 (0.46) ALDH1A1CYP1A2CYP3A4PDPK1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US claimed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 ALDH1A1 2379/4885CYP1A2 4043/4885CYP3A4 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.